[
  {
    "ts": null,
    "headline": "How Upgraded Guidance and Capital Returns at Viatris (VTRS) Have Changed Its Investment Story",
    "summary": "Viatris Inc. recently reported strong third quarter 2025 results, raising its full-year guidance to US$13.9–14.3 billion in revenue and increasing anticipated adjusted earnings per share, supported by contributions from new products and the acquisition of Aculys Pharma. Management emphasized its ongoing pursuit of growth-focused mergers and acquisitions, while also reaffirming a commitment to shareholder returns through dividends and share repurchases exceeding US$920 million...",
    "url": "https://finnhub.io/api/news?id=13ce2eaf5b16d9524e0c1561ef571263b01fc9e6df9c3d210556a1a7b6fc9f7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762596620,
      "headline": "How Upgraded Guidance and Capital Returns at Viatris (VTRS) Have Changed Its Investment Story",
      "id": 137378671,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris Inc. recently reported strong third quarter 2025 results, raising its full-year guidance to US$13.9–14.3 billion in revenue and increasing anticipated adjusted earnings per share, supported by contributions from new products and the acquisition of Aculys Pharma. Management emphasized its ongoing pursuit of growth-focused mergers and acquisitions, while also reaffirming a commitment to shareholder returns through dividends and share repurchases exceeding US$920 million...",
      "url": "https://finnhub.io/api/news?id=13ce2eaf5b16d9524e0c1561ef571263b01fc9e6df9c3d210556a1a7b6fc9f7c"
    }
  }
]